Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry [CNBC]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: CNBC
Top executives from drugmakers of all sizes met with investors to map out their plans for 2026 and beyond. Big pharma is grappling with the impact of new drug pricing deals with President Donald Trump and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs. In this article US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs . Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers of all sizes met with investors to map out their plans for 2026 and beyond at the annual JPMorgan Healthcare Conference in San Francisco. After geopolitical uncertainty weighed on dealmaking during the first half of 2025, investors and drugmakers sounded optimistic that 2026 may mark a turning point for the sector. Investors a
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi (NASDAQ:SNY) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
- Sanofi (NASDAQ:SNY) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.MarketBeat
- JPM26: Leo Pharma's growth strategy puts a spotlight on rare dermatology diseases [Yahoo! Finance]Yahoo! Finance
- State Street's crypto push, FDA delays review of Eli Lilly GLP-1 [Yahoo! Finance Canada]Yahoo! Finance Canada
- Why Sanofi May Need To Top $2.4 Billion For Ocular Therapeutix [Seeking Alpha]Seeking Alpha
SNY
Sec Filings
- 1/16/26 - Form 6-K
- 1/9/26 - Form 6-K
- 12/29/25 - Form 6-K
- SNY's page on the SEC website